Safety Profile of SARS-CoV-2 Vaccination in Patients with Lupus Nephritis: A Retrospective Study DOI Open Access
Dimitra Petrou, Smaragdi Marinaki,

Pelagia Kriki

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(2), P. 406 - 406

Published: Jan. 10, 2025

Objectives: Vaccination against SARS-CoV-2 has been vital in alleviating the spread of recent pandemic. We aimed to estimate frequency and type adverse events related vaccine patients with lupus nephritis (LN), assess its impact, if any, on risk subsequent reactivation nephritis. Methods: This was a retrospective, multicenter study which included biopsy-proven LN, who had received at least one dose. Patients ended up end-stage kidney disease (ESKD) prior vaccination or were diagnosed LN after excluded. Adverse events, systemic local, COVID-19 outcomes (full recovery, death, long COVID-19), outcome (remission, refractory disease, relapse, ESKD death), demographics, laboratory measurements, immunosuppressive regimens recorded. Results: Sixty-seven included. The median age 33 (20-46) years. Induction therapy for administered 92.5% 74.6% maintenance therapy. Of these, 94.02% remission vaccination. BNT162b2 mRNA 97.01% cases, mild symptoms 28.35% (myalgias 17.91%, headache 13.43%, arthralgias fever 10.44%) local effects 35.82% (pain 25.37%, swelling 13.43%). Overall, among upon vaccination, two (3.17%) experienced relapse within 5.75 (±0.25) months, while 75% those active achieved 21 (±2) months. Conclusions: appears safe without serious occurring, there is no significant impact clinical course disease.

Language: Английский

A systematic literature review to clarify the concept of vaccine hesitancy DOI Open Access
Daphne Bussink-Voorend, Jeannine L.A. Hautvast, Lisa Vandeberg

et al.

Nature Human Behaviour, Journal Year: 2022, Volume and Issue: 6(12), P. 1634 - 1648

Published: Aug. 22, 2022

Language: Английский

Citations

151
Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron DOI Creative Commons

Lindsey Wang,

Nathan A. Berger, David C. Kaelber

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Jan. 2, 2022

Abstract Background The Omicron SARS-CoV-2 variant is rapidly spreading in the US since December 2021 and more contagious than earlier variants. Currently, data on severity of disease caused by compared with Delta limited. Here we 3-day risks emergency department (ED) visit, hospitalization, intensive care unit (ICU) admission, mechanical ventilation patients who were first infected during a time period when was emerging to those predominant. Method This retrospective cohort study electronic health record (EHR) 577,938 first-time from multicenter, nationwide database 9/1/2021–12/24/2021, including 14,054 had their infection 12/15/2021–12/24/2021 emerged (“Emergent cohort”) 563,884 9/1/2021–12/15/2021 predominant (“Delta cohort”). After propensity-score matching cohorts, four outcomes (ED ICU ventilation) compared. Risk ratios, 95% confidence intervals (CI) calculated. Results Of Emergent (average age, 36.4 ± 24.3 years), 27.7% pediatric (<18 years old), 55.4% female, 1.8% Asian, 17.1% Black, 4.8% Hispanic, 57.3% White. differed significantly demographics, comorbidities, socio-economic determinants health. for health, medications vaccination status, consistently less half cohort: ED visit: 4.55% vs. 15.22% (risk ratio or RR: 0.30, CI: 0.28-0.33); hospitalization: 1.75% 3.95% (RR: 0.44, 0.38-0.52]); admission: 0.26% 0.78% 0.33, CI:0.23-0.48); ventilation: 0.07% 0.43% 0.16, 0.08-0.32). In children under 5 old, overall visits hospitalization 3.89% 0.96% respectively, lower 21.01% 2.65% matched (RR 0.19, 0.14-0.25; RR 0.36, 0.19-0.68). Similar trends observed other age groups (5-11, 12-17 adults (18-64 years) older (≥ 65 years). Conclusions First infections occurring at associated severe predominated.

Language: Английский

Citations

134
COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies DOI Creative Commons
Manuela Di Fusco,

Jay Lin,

Shailja Vaghela

et al.

Expert Review of Vaccines, Journal Year: 2022, Volume and Issue: 21(4), P. 435 - 451

Published: Feb. 3, 2022

From July through October of 2021, several countries issued recommendations for increased COVID-19 vaccine protection individuals with one or more immunocompromised (IC) conditions. It is critically important to understand the effectiveness (VE) vaccines among IC populations as are updated over time in response evolving pandemic.

Language: Английский

Citations

82
Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong DOI Creative Commons
Francisco Tsz Tsun Lai, Lei Huang, Celine Sze Ling Chui

et al.

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: Jan. 20, 2022

Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as ≥2 chronic conditions. We examine the potential additional risk of adverse events 28 days after first dose CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database population-based vaccination in Hong Kong, we analyze retrospective cohort patients Thirty special interest according to World Health Organization are examined. In total, 883,416 included 2,807 (0.3%) develop events. Results suggest vaccinated have lower risks than unvaccinated individuals, multimorbidity is associated increased regardless vaccination, association not modified To conclude, find no evidence that imposes extra following vaccination.

Language: Английский

Citations

77
COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in the US DOI Creative Commons

Lindsey Wang,

Nathan A. Berger, David C. Kaelber

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Feb. 22, 2022

SARS-CoV-2 infections and hospitalizations are rising in the US other countries after emergence of Omicron variant. Currently, data on infection rates, severity racial/ethnic gender disparities from is limited.

Language: Английский

Citations

58
Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy DOI Open Access
Ughetta Moscardino, Pasquale Musso, Cristiano Inguglia

et al.

Vaccine, Journal Year: 2022, Volume and Issue: 40(16), P. 2379 - 2387

Published: March 14, 2022

Language: Английский

Citations

40
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System DOI Creative Commons
Sara Y. Tartof, Jeff Slezak, Laura Puzniak

et al.

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(1), P. e2251833 - e2251833

Published: Jan. 20, 2023

Importance Immunocompromised individuals are at increased risk for severe outcomes due to SARS-CoV-2 infection. Given the varying and complex nature of COVID-19 vaccination recommendations, it is important understand vaccine uptake in this vulnerable population. Objective To assess mRNA factors associated with among immunocompromised from December 14, 2020, through August 6, 2022. Design, Setting, Participants This cohort study was conducted patients Kaiser Permanente Southern California (KPSC), an integrated health care system US. The included aged 18 years or older who were (individuals immunocompromising condition received immunosuppressive medications year prior 2020) still met criteria being 1 later. Exposures Age, sex, self-identified race ethnicity, positive test result, condition, immunomodulating medication, comorbidities, utilization, neighborhood median income. Main Outcomes Measures number doses receipt least 4 doses, estimated by hazard ratios (HRs) 95% Wald CIs via Cox proportional hazards regression. Statistical analyses between 9 23, Results Overall, 42 697 eligibility criteria. Among these, 789 (44.0%) 65 older; 20 061 (47.0%) women 22 635 (53.0%) men. With regard 4295 participants (10.1%) identified as Asian Pacific Islander, 5174 (12.1%) Black, 14 289 (33.5%) Hispanic, 17 902 (41.9%) White. As end period after accounting participant censoring death disenrollment KPSC plan, 78.0% had a third dose vaccine. Only 41.0% fourth dose, which corresponds primary series monovalent booster individuals. Uptake fifth only 0.9% following US Centers Disease Control Prevention (CDC) recommendation receive second (ie, dose). Adults (HR, 3.95 [95% CI, 3.70-4.22]) more likely compared those 44 45 64 (2.52 [2.36-2.69]). Hispanic non-Hispanic Black adults 0.77 0.74-0.80] 0.82 [0.78-0.87], respectively, White adults), documented infection (0.71 [0.62-0.81] without), receiving high-dose corticosteroids (0.88 [0.81-0.95] not) less doses. Conclusions Relevance These findings suggest that adherence CDC recommendations low. population well-established additional protection afforded targeted tailored efforts ensure remain up date warranted.

Language: Английский

Citations

25
The intention to get COVID-19 vaccine and vaccine uptake among cancer patients: An extension of the theory of planned behaviour (TPB) DOI Creative Commons
Rocco Servidio, Antonio Malvaso, Deborah Vizza

et al.

Supportive Care in Cancer, Journal Year: 2022, Volume and Issue: 30(10), P. 7973 - 7982

Published: June 25, 2022

Abstract The psychosocial impact of coronavirus disease 2019 (COVID-19) on human life is well-known. Although vaccine protection represents an effective way to control the spread virus, vaccination hesitancy may decrease individuals’ willingness get vaccinated, including among cancer patients. Therefore, objective current study was examine predictors patients’ intentions receive COVID-19 vaccinations and uptake, using integrating theory planned behaviour (TPB) health belief model (HBM). A sample 276 Italian patients (54% female 46% male) ranging from 19 85 years ( M = 49.64, SD 11.53) recruited by administering online questionnaire. results showed that with higher trust in authorities tended have vaccine-positive subjective norms, perceived under their control, viewed vaccines positively. On other hand, risk related norms but not behavioural or attitudes towards vaccination. reveals TPB variables can function effectively as mediators between risk, trust, intention vaccinate at different levels. Together, these findings suggest interventions (both public messaging personal medical communications) should focus enhancing authorities, while same time endeavouring highlight are vaccine-positive.

Language: Английский

Citations

30
COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase vaccine compliance: A systematic narrative review and meta-analysis DOI Creative Commons
Francesco Paolo Bianchi,

Pasquale Stefanizzi,

Andrea Martinelli

et al.

Vaccine, Journal Year: 2023, Volume and Issue: 41(7), P. 1303 - 1309

Published: Jan. 20, 2023

People affected by diabetes are at higher risk for complications from certain vaccine-preventable diseases. Suboptimal vaccination coverages reported in this population sub-group. The purpose of study is to estimate the proportion diabetic patients who express hesitation COVID-19 vaccine worldwide.Seven studies were included meta-analysis and systematic review, selected scientific articles available MEDLINE/PubMed, Google Scholar Scopus databases 2020 2022. following terms used search strategy: (adherence OR hesitancy compliance attitude) AND (covid* SARS*) (vaccin* immun*) (diabet*).The rate among persons with was 27.8 % (95 %CI = 15.6-41.9 %). In comparison between sexes educational status, RRs 0.90 0.71-1.15) 0.88 0.76-1.02), respectively. main reasons unwillingness lack information, opinion that unsafe or not efficient, fear adverse events.In order achieve a high coverage, multifactorial approach needed, which requires major social, health efforts. success campaign depends on capillarity consistency interventions implemented.

Language: Английский

Citations

18
COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations DOI Creative Commons
Zhipeng Yan, Ming Yang, Ching‐Lung Lai

et al.

Vaccines, Journal Year: 2021, Volume and Issue: 9(10), P. 1097 - 1097

Published: Sept. 28, 2021

COVID-19 has been spreading worldwide since late 2019. There is no definitive cure to date. Global vaccination programs are urgently required confer herd immunity, reducing the incidence of infections and associated morbidity mortality. However, a significant proportion special populations hesitant receive due their conditions, namely, age (pediatrics geriatrics), immunocompromised state, autoimmune diseases, chronic cardiovascular pulmonary active or treated cancers, pregnancy. This review aims evaluate existing evidence vaccinations on these provide clues guide decision making balance benefits risks vaccinations.

Language: Английский

Citations

39